title: Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.
abstract: The use of recombinant human erythropoietin (rHuEPO) has been controversial after myeloablative allogeneic Stem cell transplantation (allo-SCT). Reduced intensity conditioning regimens (RIC) offer a novel approach that might translate into a different profile of erythropoietic recovery. We treated 20 consecutive patients with rHuEPO early after matched sibling RIC allo-SCT. Conditioning included fludarabine, busulfan and antithymocyte globulin. EPO treatment was analyzed in terms of toxicity, impact on the frequency of Red blood cell transfusions (RBCT) and kinetics of Hemoglobin recovery within the 60 days post-allo-SCT. Results were compared with 27 matched patients who did not receive rHuEPO. In the first 2 months after allo-SCT all patients receiving rHuEPO (100%) achieved an Hb level > 11 g/dl at a median of 30 (15-35) days post-allo-SCT, as compared to only 63% of the patients not receiving rHuEPO (P = 0.007) at a median of 35 (20-55) days (P = 0.03). A total of 70% (95% CI, 50-90) of rHuEPO patients maintained an Hb over 11 g/dl in the second month as compared to only 19% (95% CI, 4-34) in the other group (P = 0.0004). For patients receiving RBCT, the use of rHuEPO was associated with a trend towards reduced RBCT requirements. This pilot study suggests a potential benefit of early administration of rHuEPO after RIC allo-SCT on early erythropoietic recovery.
authors.affiliation: Unit of Transplantation and Cellular Therapy, Institut Paoli-Calmettes, Marseille Cedex, France.
authors.forename: V
authors.initials: V
authors.lastname: Ivanov
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: K
authors.initials: K
authors.lastname: Bilger
authors.forename: P
authors.initials: P
authors.lastname: Ladaique
authors.forename: D
authors.initials: D
authors.lastname: Sainty
authors.forename: C
authors.initials: C
authors.lastname: Arnoulet
authors.forename: C
authors.initials: C
authors.lastname: Chabannon
authors.forename: N
authors.initials: N
authors.lastname: Vey
authors.forename: J
authors.initials: J
authors.lastname: Camerlo
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: V J
authors.initials: VJ
authors.lastname: Bardou
authors.forename: B
authors.initials: B
authors.lastname: Esterni
authors.forename: D
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000328:Adult; D000368:Aged; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D010865:Pilot Projects; D011994:Recombinant Proteins; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous
chemical_list: D006454:Hemoglobins; D019653:Myeloablative Agonists; D011994:Recombinant Proteins; D004921:Erythropoietin